Andrew B Mendlowitz1,2, David Naimark3, William W L Wong4, Camelia Capraru5, Jordan J Feld5, Wanrudee Isaranuwatchai2,6, Murray Krahn1,7. 1. Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada. 2. Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. 3. Department of Medicine, Sunnybrook Hospital, Toronto, ON, Canada. 4. School of Pharmacy, University of Waterloo, Waterloo, ON, Canada. 5. Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, ON, Canada. 6. St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada. 7. University Health Network - Toronto General Hospital, Toronto, ON, Canada.
Abstract
BACKGROUND AND AIMS: The World Health Organization's hepatitis C virus (HCV) elimination strategy recognizes the need for interventions that identify populations most affected by infection. The emergency department (ED) has been suggested as a setting for HCV screening. The study objective was to explore the health and economic impact of HCV screening in the ED setting. METHODS: We used a microsimulation model to conduct a cost-utility analysis evaluating two ED setting-specific strategies: no screening, and screening and subsequent treatment. Strategies were examined for two populations: (a) the general ED patient population; and (b) ED patients born between 1945 and 1975. The analysis was conducted from a healthcare payer perspective over a lifetime time horizon. A reference and high ED HCV seroprevalence measure were examined in the Canadian healthcare setting.US costs of chronic infection were used for a scenario analysis of screening in the US healthcare setting. RESULTS: For birth cohort screening, in comparison to no screening, one liver-related death was averted for every 760 and 123 persons screened for the reference and high seroprevalence measures. For general population screening, one liver-related death was averted for every 831 and 147 persons screened for the reference and high seroprevalence measures. In comparison to no screening, birth cohort screening was cost-effective at CAN$25,584/quality-adjusted life year (QALY) and US$42,615/QALY. General population screening was cost-effective at CAN$19,733/QALY and US$32,187/QALY. CONCLUSIONS: ED screening may represent a cost-effective component of population-based strategies to eliminate HCV. Further studies are warranted to explore the feasibility and acceptability of this approach.
BACKGROUND AND AIMS: The World Health Organization's hepatitis C virus (HCV) elimination strategy recognizes the need for interventions that identify populations most affected by infection. The emergency department (ED) has been suggested as a setting for HCV screening. The study objective was to explore the health and economic impact of HCV screening in the ED setting. METHODS: We used a microsimulation model to conduct a cost-utility analysis evaluating two ED setting-specific strategies: no screening, and screening and subsequent treatment. Strategies were examined for two populations: (a) the general ED patient population; and (b) ED patients born between 1945 and 1975. The analysis was conducted from a healthcare payer perspective over a lifetime time horizon. A reference and high ED HCV seroprevalence measure were examined in the Canadian healthcare setting.US costs of chronic infection were used for a scenario analysis of screening in the US healthcare setting. RESULTS: For birth cohort screening, in comparison to no screening, one liver-related death was averted for every 760 and 123 persons screened for the reference and high seroprevalence measures. For general population screening, one liver-related death was averted for every 831 and 147 persons screened for the reference and high seroprevalence measures. In comparison to no screening, birth cohort screening was cost-effective at CAN$25,584/quality-adjusted life year (QALY) and US$42,615/QALY. General population screening was cost-effective at CAN$19,733/QALY and US$32,187/QALY. CONCLUSIONS: ED screening may represent a cost-effective component of population-based strategies to eliminate HCV. Further studies are warranted to explore the feasibility and acceptability of this approach.
Authors: Mia J Biondi; Grishma Hirode; Camelia Capraru; Aaron Vanderhoff; Joel Karkada; Brett Wolfson-Stofko; David Smookler; Steven M Friedman; Kathy Bates; Tony Mazzulli; Joshua V Juan; Hemant Shah; Bettina E Hansen; Jordan J Feld; Harry LA Janssen Journal: Can Liver J Date: 2022-08-16
Authors: Jason Zucker; Lawrence Purpura; Fereshteh Sani; Simian Huang; Aaron Schluger; Kenneth Ruperto; Jacek Slowkowski; Susan Olender; Matt Scherer; Delivette Castor; Peter Gordon Journal: AIDS Patient Care STDS Date: 2022-03 Impact factor: 5.944
Authors: Paul G Carty; Christopher G Fawsitt; Paddy Gillespie; Patricia Harrington; Michelle O'Neill; Susan M Smith; Conor Teljeur; Mairin Ryan Journal: Appl Health Econ Health Policy Date: 2021-12-06 Impact factor: 3.686
Authors: James S Ford; Tasleem Chechi; Kavian Toosi; Bilawal Mahmood; Dillon Meehleis; Michella Otmar; Nam Tran; Larissa May Journal: West J Emerg Med Date: 2021-05-14